GlobeNewsWire
20 Aug 2026, 11:30 UTC · 3h ago
Evaxion announces business update and second quarter 2026 financial results
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
20 Aug 2026, 11:30 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Evaxion will present three-year clinical efficacy data for its lead personalized cancer vaccine, EVX-01, at the ESMO Congress in October 2026. — Long-term efficacy data for a lead asset in a Phase 2 trial is a primary catalyst for clinical-stage biotech valuations.
+0.80The company expects to submit a regulatory filing for clinical testing of its off-the-shelf AML vaccine, EVX-04, before the end of 2026. — Moving a candidate from preclinical to clinical stages represents a significant de-risking event and pipeline progression.
+0.60Evaxion plans to expand its AI-Immunology platform into the autoimmune disease space in the second half of 2026. — Expanding the total addressable market (TAM) to include autoimmune diseases adds long-term optionality but has immediate low impact.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Preclinical data for EVX-04 demonstrates successful expression, secretion, and targeted cell-killing in human cells and mice. — Positive preclinical results provide supporting evidence for the platform's validity but are secondary to human clinical data.
+0.20Which stocks this story touches
The company reported steady progress toward 2026 milestones, pipeline expansion, and positive preclinical data for its vaccine candidates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
54m ago
